455 related articles for article (PubMed ID: 26301799)
1. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer.
Nguyen-Ngoc T; Bouchaab H; Adjei AA; Peters S
J Thorac Oncol; 2015 Oct; 10(10):1396-403. PubMed ID: 26301799
[TBL] [Abstract][Full Text] [Related]
2. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
6. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
7. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D
Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
9. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
Turshudzhyan A; Vredenburgh J
Curr Oncol; 2020 Dec; 28(1):196-202. PubMed ID: 33704186
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
[No Abstract] [Full Text] [Related]
11. [Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].
Kang X; Zhu N; Song X
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):711-714. PubMed ID: 27760604
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer].
Liu X; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
[TBL] [Abstract][Full Text] [Related]
13. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F; Pisano C; Mazieres J; Mezquita L; Nadal E; Planchard D; Pradines A; Santamaria D; Swalduz A; Ambrogio C; Novello S; Ortiz-Cuaran S;
Cancer Treat Rev; 2022 Feb; 103():102335. PubMed ID: 35033867
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
15. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R; de Castro G; Gil-Bazo I; Caglevic C; Calogero R; Giallombardo M; Santos ES; Raez LE; Rolfo C
Crit Rev Oncol Hematol; 2016 May; 101():32-9. PubMed ID: 26960735
[TBL] [Abstract][Full Text] [Related]
16. Dabrafenib and trametinib for the treatment of non-small cell lung cancer.
Kelly RJ
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1063-1068. PubMed ID: 30198802
[TBL] [Abstract][Full Text] [Related]
17. Targeting of MEK in lung cancer therapeutics.
Heigener DF; Gandara DR; Reck M
Lancet Respir Med; 2015 Apr; 3(4):319-27. PubMed ID: 25801412
[TBL] [Abstract][Full Text] [Related]
18. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
[No Abstract] [Full Text] [Related]
19. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O; Milia J; Cabarrou B; Bluthgen MV; Besse B; Smit EF; Wolf J; Peters S; Früh M; Koeberle D; Oulkhouir Y; Schuler M; Curioni-Fontecedro A; Huret B; Kerjouan M; Michels S; Pall G; Rothschild S; Schmid-Bindert G; Scheffler M; Veillon R; Wannesson L; Diebold J; Zalcman G; Filleron T; Mazières J
J Thorac Oncol; 2015 Oct; 10(10):1451-7. PubMed ID: 26200454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]